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Midkine (MK; a low molecular weight heparin-binding growth factor) is a multifunctional 
cytokine. MK plays a role in morphogenesis of many organs including teeth through 
epithelial-mesenchymal interactions. We immunohistochemically examined MK expression 
in various human odontogenic tumors. There was no difference in positive rate and 
intensity of MK between benign odontogenic tumors and their malignant counterparts. 
Ameloblastoma showed MK localization in the peripheral columnar cells in budding 
processes from the parenchyma, which frequently expressed proliferating cell nuclear 
antigen (PCNA). MK was also preferentially expressed in keratinized cells in 
acanthomatous ameloblastoma and keratocystic odontogenic tumor. In odontogenic mixed 
tumors except for odontoma, intense immunoreactivity to MK was found in epithelial 
follicles, the surrounding odontogenic ectomesenchymal tissue, and the basement 
membrane between them. Intensity in the odontogenic ectomesenchyme decreased in 
relation to distance from the epithelial follicles. No expression was found in tumor cells 
associated with production of dental hard tissues in odontogenic mixed tumors including 
odontoma. These findings suggested that MK is involved in the reciprocal interaction 
between odontogenic epithelium and odontogenic ectomesenchymal tissue in areas without 
dental hard tissue formation in odontogenic mixed tumors. Co-expression of MK and 
PCNA was also observed in epithelial follicles and highly cellular nodules in the 
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ectomesenchyme of odontogenic mixed tumors. MK is considered to mediate growth 
activity of odontogenic tumors and cell differentiation of odontogenic mixed tumors 
through molecular mechanisms similar to those involved in morphogenesis of the tooth. 
 
Abbreviations: MK, midkine; PCNA, proliferating cell nuclear antigen 
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1. Introduction 
Midkine (MK) is a low molecular weight heparin-binding growth factor. This 
cytokine is highly expressed in the mid-gestational period during embryogenesis. MK 
participates in cell growth, survival, migration, neurogenesis, and carcinogenesis. MK is 
involved also in morphogenesis of various organs through epithelial-mesenchymal 
interactions. [1-6] 
In the morphogenesis of the tooth, enamel and dentin matrices are produced by 
ameloblasts and odontoblasts, respectively. Ameloblasts are derived from odontogenic 
epithelial elements, and odontoblasts differentiate from odontogenic ectomesenchymal 
tissue in the tooth germ. These epithelial and mesenchymal differentiations do not 
independently occur, but are induced through the intermediary interaction between 
odontogenic epithelial and ectomesenchymal components. [7,8] Therefore, tooth germ is 
regarded as one of the good morphogenetic models for epithelial-mesenchymal interactions. 
Mitsiadis et al. observed the regulation of MK gene and protein expression by 
epithelial-mesenchymal interaction in the tooth germ, and suggested an important role for 
MK in the molecular cascade that controls tooth development. [9] 
The MK expression in odontogenic tumors has not been investigated. Odontogenic 
tumors are histologically divided by WHO into several categories, depending on their 
constituent components, as follows: [10] 
Benign 
1) Tumors comprising odontogenic epithelium with mature, fibrous stroma without 
odontogenic ectomesenchyme 
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2) Tumors comprising odontogenic epithelium with odontogenic ectomesenchyme, with or 
without dental hard tissue formation 
3) Tumors comprising mesenchyme and/or odontogenic ectomesenchyme with or without 
odontogenic epithelium 
Malignant 
1) Odontogenic carcinomas 
2) Odontogenic sarcomas 
Ameloblastoma, ameloblastic carcinoma, keratocystic odontogenic tumor, and 
adenomatoid odontogenic tumor are composed of odontogenic epithelium with mature, 
fibrous stroma without odontogenic ectomesenchyme. Ameloblastic fibroma and 
ameloblastic fibrosarcoma are tumors characterized by odontogenic epithelium with 
odontogenic ectomesenchyme, without dental hard tissue formation. Odontoma, 
ameloblastic fibrodentinoma, and ameloblastic fibro-odontoma are categorized as tumors 
comprised of odontogenic epithelium with odontogenic ectomesenchyme, with dental hard 
tissue formation. Almost all tumors possessing dental hard tissue formation contain 
neoplastic ameloblasts and/or odontoblasts associated with production of enamel and dentin 
matrices, respectively. 
To investigate whether MK participates in the construction of characteristic 
histological structures in these tumors, we looked at their MK immunoexpression. 
 
2. Materials and methods 
 We investigated 141 cases of human odontogenic tumors including ameloblastoma 
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(55), ameloblastic carcinoma (3), keratocystic odontogenic tumor (28), adenomatoid 
odontogenic tumor (4), odontoma (compound type (24) and complex type (15)), 
ameloblastic fibroma (3), ameloblastic fibrodentinoma, ameloblastic fibro-odontoma (7), 
and ameloblastic fibrosarcoma (2). Specimens were retrieved from the histopathological 
files of the Division of Oral Pathology and Bone Metabolism, Unit of Basic Medical 
Sciences, Course of Medical and Dental Sciences, Nagasaki University Graduate School of 
Biomedical Sciences. The specimens were fixed in 10% neutral buffered formalin fixative, 
decalcified with formic acid where necessary, embedded in paraffin, cut into 3-μm-thick 
sections, and stained with hematoxylin and eosin (HE). Table 1 summarizes the clinical 
data of all the patients. 
For the investigation of MK expression, we employed a mouse anti-human MK 
monoclonal antibody (TFB Inc., Tokyo, Japan) as the primary antibody. To evaluate the 
relationship with cell growth, a mouse anti-human proliferating cell nuclear antigen 
(PCNA) monoclonal antibody (DakoCytomation Co., Ltd., Kyoto, Japan) was applied after 
the retrieval of PCNA in 0.01 M citrate buffer (pH: 6.0) by heating (121ºC, 10 min) in an 
autoclave. Immunostaining was carried out using the EnVision + system (DakoCytomation). 
The chromogen 3,3’-diaminobenzidine (Sigma-Aldrich Japan, Tokyo) was used to reveal 
the sites of peroxidase activity. After counterstaining the sections with hematoxylin, they 
were dehydrated and mounted in a synthetic mounting medium. 
 
3. Results 
A brief summary of the results is shown in Table 2. 
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3.1. Ameloblastoma 
 MK localization was found in 30 of 55 ameloblastomas (54.5%). The columnar 
epithelial cells at the periphery of the parenchyma, especially in cells projecting from 
epithelial nests, showed immunoreaction with MK in their cytoplasm. However, not all 
peripheral cells were uniformly positive; patchy positivity was observed in the periphery of 
the nests. Faint or absent expression were noted in the fibroblasts of the stroma (Fig. 1a). 
MK was expressed also in squamous metaplastic areas or the acanthomatous patterns of 
ameloblastoma, which were composed of epithelial cells with eosinophilic abundant 
cytoplasm suggesting keratinization (Fig. 1b). PCNA was frequently expressed in the 
nuclei of the peripheral columnar cells rather than the central cells. Particularly columnar 
cells in projections budding from the nests exhibited intense immunostaining for PCNA 
(Fig. 1c). 
3.2. Ameloblastic carcinoma 
 Two of 3 ameloblastic carcinomas were positive for MK (66.7%), with 
localization in practically the entire peripheral columnar epithelium of tumor parenchyma. 
Stroma showed no MK expression. There was no noticeable difference in positive rate and 
staining intensity between benign ameloblastomas and ameloblastic carcinomas. 
3.3. Keratocystic odontogenic tumor 
 MK was expressed in 11 of 28 keratocystic odontogenic tumors (39.3%). We 
found intense reactivity in the neoplastic epithelium and exfoliated keratin (Fig. 2). 
Invaginated epithelium into the fibrous stroma from keratinized squamous epithelium 
lining the cyst wall, and epithelium of daughter cysts, showed immunolocalization. 
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3.4. Adenomatoid odontogenic tumor 
No MK expression was seen in the parenchyma and stroma in all cases. 
3.5. Odontoma 
 We observed MK expression only in 1 of 24 compound type odontomas (4.2%) 
and 2 of 15 complex type odontomas (13.3%). There was no expression in dental hard 
tissues, reduced ameloblasts, differentiated pulp cells, and odontoblasts (Fig. 3), whereas 
small nodules of odontogenic ectomesenchymal tissue and round islands of odontogenic 
epithelium in the tumor had MK expression. The latter cellular components were not 
associated with production of dental hard tissues. 
3.6. Ameloblastic fibroma 
 Immunoreactivity was stronger in all ameloblastic fibromas than ameloblastomas. 
MK was expressed in follicular epithelial elements like the enamel organ of tooth germ and 
surrounding odontogenic ectomesenchymal tissue. The positive tumor cells exhibited 
cytoplasmic and nuclear reaction. The intensity of expression in the ectomesenchyme was 
weaker with increasing distance from the epithelial follicles (Fig. 4a). Basement membrane 
circumscribing epithelial follicles and some highly cellular areas of odontogenic 
ectomesenchyme were strongly MK positive (Fig. 4b). PCNA was expressed both in 
epithelial and ectomesenchymal tissues. Especially, peripheral columnar cells were strongly 
positive, whereas the ectomesenchymal cells adjacent to the epithelial follicles infrequently 
showed reactivity to PCNA. In the ectomesenchymal area, highly cellular nodules 
demonstrated intense PCNA expression with distribution similar to that of MK (Fig. 4c). 
3.7. Ameloblastic fibrodentinoma and fibro-odontoma 
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 All ameloblastic fibrodentinomas and fibro-odontomas were positive for MK, and 
its distribution in areas without dental hard tissue formation was similar to that of 
ameloblastic fibroma. Participants in hard tissue production, including epithelial islands 
and ectomesenchymal cells adhering to or near the dental hard tissue, showed very faint or 
no expression of MK. Basement membrane around the epithelial elements in this hard 
tissue-producing area exhibited no expression (Fig. 5). 
3.8. Ameloblastic fibrosarcoma 
 All ameloblastic fibrosarcomas showed strong MK expression in both the 
epithelial follicles and surrounding ectomesenchymal components. Although the 
ectomesenchymal tissues exhibited diffuse MK expression, no difference in intensity of 
MK expression was noted between ameloblastic fibroma and ameloblastic fibrosarcoma. 
 
4. Discussion 
 MK is involved in carcinogenesis and cancer-related angiogenic, fibrinolytic, 
chemotactic, mitogenic, anti-apoptotic, and transforming activities. [1,2,4] Therefore, 
various carcinomas express MK, and serum MK level increases in some carcinomas 
including hepatocellular carcinoma and gastrointestinal carcinomas. [11-13] In the present 
study, there was no difference in positive rate or intensity of MK expression between 
benign odontogenic tumors and their malignant counterparts (Table 2). These data suggest 
that MK cannot be used as a marker to distinguish malignant from nonmalignant 
odontogenic tumors. 
Sandra et al. found immunohistochemical expression of MK in 70% of 
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ameloblastoma cases and high MK labeling index in the outer cells of the parenchyma. [14] 
They concluded that MK played an important role in the growth of ameloblastoma, after 
observing that the level of MK expression reflected the growth rate of ameloblastoma. We 
also preferentially detected MK expression in columnar epithelium projecting from the 
parenchyma of ameloblastomas. WHO defined solid/multicystic type ameloblastoma 
(conventional ameloblastoma) as a slowly growing, locally invasive, epithelial odontogenic 
tumor of the jaws with a high rate of recurrence if not removed adequately, but with 
virtually no tendency to metastasize. [10] These MK-positive cells were virtually all 
PCNA-positive and suggested that MK was associated with local aggressiveness and/or 
growth activity of odontogenic tumors. The absence of MK expression in adenomatoid 
odontogenic tumors, which are usually nonaggressive, supports this hypothesis. 
 Interestingly, relatively strong expression of MK was detected in squamous 
metaplastic areas of the acanthomatous ameloblastoma. Keratinized odontogenic 
epithelium was MK positive in 39.3% of keratocystic odontogenic tumors. MK may 
participate in keratinization of epithelial cells, because it is expressed more intensely in 
well-differentiated than poorly differentiated squamous cell carcinoma in esophageal and 
vulvar regions. [15,16] In addition to the epithelium with exfoliated keratin, MK expression 
was observed in invaginated epithelium from cyst wall and epithelium of daughter cysts. 
These findings suggest that the expression profile of MK correlates with local 
aggressiveness and/or growth activity of keratocystic odontogenic tumors. 
 MK expression also correlates closely with morphogenesis of various organs 
regulated through epithelial-mesenchymal interactions. [1-6] Physiological morphogenesis 
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and cell differentiation in tooth development are regulated by a series of 
epithelial-mesenchymal interactions. [7,8,17] Many transcription and signaling factors are 
associated with reciprocal interactions involved in tooth development. [18-27] Various 
odontogenic tumors histologically mimic the odontogenic tissues that participate in tooth 
development. Thus some factors involved in tooth development have been 
immunohistochemically revealed in odontogenic tumors. [28-34] Mitsiadis et al. [9] 
investigated MK expression in tooth development of mice and found that the distribution of 
MK expression depended on the developmental stage of the tooth germ. In the late bell 
stage without dental hard tissue formation, intense MK localization was found in the inner 
enamel epithelium, whole dental papilla, and the basement membrane between them. In 
contrast, in the late bell stage with dental hard tissue formation, MK expression was absent 
from all dental cells in the crown region. Therefore, inner enamel epithelium and 
differentiating ectomesenchymal cells showed MK localization, whereas MK localization 
in ameloblasts, odontoblasts, and pulp cells diminished after their terminal differentiation. 
The distribution of MK in ameloblastic fibroma and ameloblastic fibrosarcoma 
closely resembled that in the bell stage without dental hard tissue formation, and MK 
localization in the basement membrane indicated signaling of reciprocal interaction 
between epithelial follicles and ectomesenchymal tissue. [9] Odontoma is regarded as a 
hamartoma and also mixed tumor histologically composed predominantly of dental hard 
tissues, i.e., dentin, enamel, and cementum. It contains also a small amount of odontogenic 
epithelium and ectomesenchyme. Its cellular elements include reduced ameloblasts, 
odontoblasts, and pulp cells after terminal differentiation. [10] In our study, the tumor cells 
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adjacent to the dental hard tissues in odontoma showed no MK expression. In ameloblastic 
fibrodentinoma and fibro-odontoma, no MK localization occurred in the epithelial or 
mesenchymal cells adhering to the hard tissue, which were thought to take part in formation 
of the hard tissues. It is indicated that MK participates in the process of differentiation, and 
its expression decreases upon completion of differentiation and acquisition of function in 
odontogenic tumors, corresponding to the development of the mouse tooth. [9] Moreover, 
PCNA was frequently expressed in epithelial follicles and ectomesenchymal cells present 
in the high cellularity area of the odontogenic mixed tumor, and similar in distribution to 
that of MK expression. Co-expression of MK and PCNA suggested that MK is also 
involved in cell growth of odontogenic mixed tumors other than odontoma. 
 In conclusion, no difference in MK-positive rate and intensity was revealed 
between benign odontogenic tumors and their malignant counterparts, but our results 
suggest that the level of expression was correlated with local growth activity of 
odontogenic tumors. MK was frequently expressed in odontogenic mixed tumors except for 
odontoma, which contain tumor cells that have not completely differentiated. It is suggested 
that MK mediates epithelial-mesenchymal interactions in odontogenic mixed tumors as 
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Table 1. Odontogenic tumors included in this study 
 
Histology   No. of cases      Sex    Average age at 
        Male Female    first visit 
Ameloblastoma   55    33  22  42.8 
Ameloblastic carcinoma   3     2   1  66.7 
Keratocystic odontogenic tumor 28    15  13  34.0 
Adenomatoid odontogenic tumor  4     1   3  23.5 
Odontoma   39    16  23  24.0 
 Compound    (24       8    16     20.9) 
 Complex    (15             8     7     29.0) 
Ameloblastic fibroma   3     2   1  19.0 
Ameloblastic fibrodentinoma  7     4   3  13.0 
 and fibro-odontoma 
Ameloblastic fibrosarcoma  2     1   1  26.5 
   total         141    74  67 
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Table 2. Expression of MK in odontogenic tumors 
 
Histology (no. of cases)  No. of positive cases Localization 
Ameloblastoma (55)     30 (54.5%)  peripheral columnar cells 
       squamous metaplasia 
Ameloblastic carcinoma (3)      2 (66.7%)  peripheral columnar cells 
       squamous metaplasia 
Keratocystic odontogenic tumor (28)    11 (39.3%)  squamous epithelium 
Adenomatoid odontogenic tumor (4)     0 (0%) 
Odontoma (39)       3 (7.7%)     
Compound (24)          1 (4.2%)  islands of odontogenic epithelium* 
Complex (15)     2 (13.3%) islands of odontogenic epithelium 
    and ectomesenchyme* 
Ameloblastic fibroma (3)      3 (100%)  epithelial elements and their 
surrounding odontogenic 
ectomesenchyme 
Ameloblastic fibrodentinoma 7 (100%)  epithelial elements and their 
and fibro-odontoma (7)    surrounding odontogenic 
ectomesenchyme* 








Figure 1. Ameloblastoma expressing MK (a, b) and PCNA (c). (a) Partial peripheral 
columnar epithelium shows cytoplasmic expression of MK. Stromal fibroblasts 
exhibit weak immunoreaction. (b) Large keratinocyte-like cells in squamous 
metaplastic areas also demonstrate intense expression. (c) The cells in the 
projections budding from epithelial nests are strongly positive for PCNA. 
Figure 2. Keratocystic odontogenic tumor. MK expression is found in the neoplastic 
epithelium and exfoliated keratin materials. 
Figure 3. Mature dentin and pulp in compound odontoma immunostained with MK. No 
expression is observed in pulp cells, odontoblasts, dentinal fibers, and dentin. 
Figure 4. Ameloblastic fibroma expressing MK (a, b) and PCNA (c). (a) Intense 
immunoreaction with MK is observed in epithelial follicles (E) and surrounding 
odontogenic ectomesenchymal tissue. Intensity of expression is weak away from 
the epithelium. (b) Epithelial components and accumulation of odontogenic 
ectomesenchymal cells show strong MK expression. Basement membrane around 
the epithelial follicles is also positive. (c) Epithelial follicles and the highly 
cellular area in ectomesenchymal tissue demonstrate strong immunoreaction to 
PCNA. 
Figure 5. Immature dentin (D) in ameloblastic fibrodentinoma. MK is not localized in both 
the odontogenic epithelium (arrows) and odontogenic ectomesenchymal cells 
(arrow heads) near the dentin. 
 21
Fig. 1a 
 
 
 
 
 
 
 
Fig. 1b 
 
 
 
 
 
 
Fig. 1c 
 22
Fig. 2 
 
 
 
 
 
 
 
Fig. 3 
 
 
 
 
 
 
Fig. 4a 
 23
Fig. 4b 
 
 
 
 
 
 
 
Fig. 4c 
 
 
 
 
 
 
Fig. 5 
